A Phase 1 safety and feasibility with HIV-positive individuals to test the T cells generated after using MVA-VLP HIV vaccine

Trial Profile

A Phase 1 safety and feasibility with HIV-positive individuals to test the T cells generated after using MVA-VLP HIV vaccine

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs MVA-VLP-HIv-Vaccine/lentivirus-therapy-AGT/GeoVax (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Apr 2017 According to an American Gene Technologies International media release, company intends to initiate this trial later in 2017.
    • 03 Apr 2017 New trial record
    • 14 Mar 2017 According to a GeoVax Labs media release, company has collaboration with American Gene Technologies International Inc. (AGT) for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top